SCHEMBL12190897

SCHEMBL12190897

Cc1ccc(C)c(NC(=O)c2cncc(-c3ccc(O)cc3)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.55
SCN10A Q9Y5Y9 4/20 0.53
RAB9A P51151 3/20 0.52
NPC1 O15118 1/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KCNH2 Q12809 2/20 0.52
CCNC P24863 2/20 0.50
CDK8 P49336 2/20 0.50
APOBEC3A P31941 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HDAC1 Q13547 1/20 0.46
TP53 P04637 2/20 0.46
AAK1 Q2M2I8 1/20 0.45
ALDH1A1 P00352 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12191075 0.89 SCN10A (0.68) CHRNA7SCN10ARAB9ANPC1GAA
SCHEMBL12190902 0.88 SCN10A (0.60) CHRNA7SCN10AGAAKCNH2CCNC
SCHEMBL12191145 0.88 RAB9A (0.52) CHRNA7SCN10ARAB9ANPC1GAA
SCHEMBL12190908 0.86 CCNC (0.65) CHRNA7SCN10ARAB9ANPC1GAA
SCHEMBL12191125 0.83 ALDH1A1 (0.51) CHRNA7SCN10ARAB9ANPC1GAA
SCHEMBL23409003 0.81 APOBEC3A (0.66) RAB9ANPC1GAASMN1; SMN2APOBEC3A
SCHEMBL12190847 0.81 NPC1 (0.55) CHRNA7RAB9ANPC1GAASMN1; SMN2
SCHEMBL14573319 0.80 CHRNA7 (0.70) CHRNA7SCN10AKCNH2CCNCCDK8
SCHEMBL12191120 0.79 MEN1 (0.52) CHRNA7RAB9ANPC1GAASMN1; SMN2
SCHEMBL12191009 0.79 HCK (0.61) CHRNA7RAB9ANPC1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569907-B1 NICOTINAMIDE-BASED KINASE INHIBITORS YM BIOSCIENCES AUSTRALIA PTY (AU) 2016-03-09 EP disclosed
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-8030336-B2 Nicotinamide-based kinase inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-10-04 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed
US-20070060619-A1 Nicotinamide-based kinase inhibitors CYTOPIA PTY LTD (AU) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060619-A1 Nicotinamide-based kinase inhibitors NADK, NAMPT, PDXK CHRNA7 2406/4885SCN10A 1066/4885RAB9A 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.